Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice
- 501 Downloads
Depression associated with obesity remains an interesting area to study the biological mechanisms and novel therapeutic intervention.
The present study investigates the effect of a novel 5-HT3 receptor antagonist 3-methoxy-N-p-tolylquinoxalin-2-carboxamide (QCM-4) on several pathogenic markers of depression associated with obesity such as plasma insulin resistance, hippocampal cyclic adenosine monophosphate (cAMP), brain-derived neurotrophic factor (BDNF), serotonin (5-HT) concentrations, hippocampal neuronal damage, and p53 protein expression in high-fat-diet (HFD)-fed mice.
Obesity was experimentally induced in mice by feeding with HFD for 14 weeks followed by administration of QCM-4 (1 and 2 mg/kg, p.o.)/standard escitalopram (ESC) (10 mg/kg, p.o.)/vehicle (10 ml/kg, p.o.) for 28 days. Behavioral assays such as sucrose preference test (SPT); forced swim test (FST); elevated plus maze (EPM); biochemical assays including oral glucose tolerance tests (OGTT), insulin, cAMP, BDNF, and 5-HT concentrations; and molecular assays mainly histology and immunohistochemistry (IHC) of p53 protein in the dentate gyrus (DG), CA1, and CA3 regions of hippocampus in HFD fed mice were performed.
Chronic treatment with QCM-4 in HFD-fed mice reversed the behavioral alterations in SPT, FST, and EPM. QCM-4 showed poor sensitivity for plasma glucose, improved insulin sensitivity, increased hippocampal cAMP, BDNF, and 5-HT concentrations. In the hippocampal DG, CA1, and CA3 regions, QCM-4 treatment improved the neuronal morphology in the histopathology and inhibited p53 protein expression in IHC assay in HFD-fed mice.
QCM-4 attenuated the depressive-like phenotype in HFD-fed mice by improving behavioral, biochemical, and molecular alterations through serotonergic neuromodulation.
KeywordsDepression Obesity Serotonin p53 BDNF
The authors are thankful to Birla Institute of Technology and Science (BITS), Pilani, India, for providing the support and research facilities to pursue this work.
- Amin SN, Younan SM, Youssef MF, Rashed LA, Mohamady I (2013) A histological and functional study on hippocampal formation of normal and diabetic rats. F1000 Research 2.Google Scholar
- Awada R, Parimisetty A, d’Hellencourt CL (2013) Influence of obesity on neurodegenerative diseases. Neurodegener Dis. doi: 10.5772/53671
- Boissier JR, Simon P (1965) Action de la caféine sur la motilité spontanée de la souris. Ach Int Pharmacodyn Ther 158:212–221Google Scholar
- Ferres-Coy A, Pilar-Cuellar F, Vidal R, Paz V, Masana M, Cortes R, Carmona MC, Campa L, Pazos A, Montefeltro A, Valdizan EM, Artigas F, Bortolozzi A (2013) RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis. Transl Psychiatry 3:e211CrossRefPubMedPubMedCentralGoogle Scholar
- Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA (2010) A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr 46:212–223CrossRefPubMedPubMedCentralGoogle Scholar
- Mørk A, Pehrson L, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB (2012) Pharmacological effects of LU AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340:666–675CrossRefPubMedGoogle Scholar
- Rosgan NL, Carter MS, Elman S, Bauer M, Love M, Korenman SG (2002) Common treatment of polysystic ovary syndrome and major depressive disorder: case study and review. Curr Drug Targets Immune Endocr Metabol Disord 2:91–102Google Scholar
- Spiers JG, Chen HJC, Sernia C, Lavidis NA (2014) Activation of the hypothalamic-pituitary-adrenal stress axis induces cellular oxidative stress. Front Neurosci 8:1–6Google Scholar
- Xu Y, Jones JE, Lauzon DA, Anderson JG, Balthasar N et al (2010) A serotonin and melanocortin circuit mediates D-fenfluramine anorexia. J Neurosci 30:14630–14634Google Scholar